Jacobs Levy Equity Management’s Organogenesis Holdings ORGO Stock Holding History

Jacobs Levy Equity Management’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-47,516	Closed	-$205K	–	1130
2025 Q1	$205K	Sell	47,516 -1,097	-2%	-$4.43K	﹤0.01%	1027
2024 Q4	$156K	Sell	48,613 -232,865	-83%	-$781K	﹤0.01%	908
2024 Q3	$805K	Sell	281,478 -148,326	-35%	-$416K	﹤0.01%	767
2024 Q2	$1.2M	Buy	429,804 +243,568	+131%	+$654K	0.01%	692
2024 Q1	$529K	Buy	186,236 +144,771	+349%	+$492K	﹤0.01%	813
2023 Q4	$170K	Buy	+41,465	New	+$116K	﹤0.01%	936
2023 Q2	–	Sell	-867,261	Closed	-$1.85M	–	1050
2023 Q1	$1.85M	Buy	+867,261	New	+$2.14M	0.01%	588

Other funds holding ORGO

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's ORGO Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of Organogenesis Holdings (ORGO) in Q2 2025, closing a stake of 47,516 shares — an estimated $205K sold.

Jacobs Levy Equity Management first reported a position in ORGO in Q1 2023 and held it in 7 quarters. The position peaked at $1.85M in Q1 2023. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2025.

Jacobs Levy Equity Management reported no remaining Organogenesis Holdings position as of Q2 2025 after selling out during the quarter.
Jacobs Levy Equity Management sold 47,516 Organogenesis Holdings shares in Q2 2025, an estimated $205K.
Jacobs Levy Equity Management first reported a position in Organogenesis Holdings in Q1 2023 and held it in 7 quarters.
Jacobs Levy Equity Management's Organogenesis Holdings position peaked at $1.85M in Q1 2023.
115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.